HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Atossa Therapeutics, maintaining a price target of $6. This suggests confidence in the company's future performance.
October 31, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Atossa Therapeutics, maintaining a price target of $6. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $6 price target by HC Wainwright & Co. indicates a positive outlook for Atossa Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100